| Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline JR Brahmer, C Lacchetti, BJ Schneider, MB Atkins, KJ Brassil, ... Journal of Clinical Oncology 36 (17), 1714-1768, 2018 | 3851 | 2018 |
| Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update BJ Schneider, J Naidoo, BD Santomasso, C Lacchetti, S Adkins, ... Journal of Clinical Oncology 39 (36), 4073-4126, 2021 | 1290 | 2021 |
| Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative AM Tsimberidou, NG Iskander, DS Hong, JJ Wheler, GS Falchook, S Fu, ... Clinical cancer research 18 (22), 6373-6383, 2012 | 609 | 2012 |
| A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer PA Ott, S Hu-Lieskovan, B Chmielowski, R Govindan, A Naing, ... Cell 183 (2), 347-362. e24, 2020 | 536 | 2020 |
| PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations F Janku, JJ Wheler, SN Westin, SL Moulder, A Naing, AM Tsimberidou, ... Journal of clinical oncology 30 (8), 777-782, 2012 | 529 | 2012 |
| PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors F Janku, AM Tsimberidou, I Garrido-Laguna, X Wang, R Luthra, DS Hong, ... Molecular cancer therapeutics 10 (3), 558-565, 2011 | 443 | 2011 |
| Targeting the indoleamine 2, 3-dioxygenase pathway in cancer YW Moon, J Hajjar, P Hwu, A Naing Journal for immunotherapy of cancer 3, 1-10, 2015 | 368 | 2015 |
| Combining radiation and immunotherapy: a new systemic therapy for solid tumors? C Tang, X Wang, H Soh, S Seyedin, MA Cortez, S Krishnan, E Massarelli, ... Cancer immunology research 2 (9), 831-838, 2014 | 337 | 2014 |
| PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials F Janku, JJ Wheler, A Naing, GS Falchook, DS Hong, VM Stepanek, S Fu, ... Cancer research 73 (1), 276-284, 2013 | 326 | 2013 |
| Ipilimumab with stereotactic ablative radiation therapy: phase I results and immunologic correlates from peripheral T cells C Tang, JW Welsh, P De Groot, E Massarelli, JY Chang, KR Hess, S Basu, ... Clinical Cancer Research 23 (6), 1388-1396, 2017 | 313 | 2017 |
| Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center M Ayala-Ramirez, S Jasim, L Feng, S Ejaz, F Deniz, N Busaidy, ... European journal of endocrinology 169 (6), 891-899, 2013 | 310 | 2013 |
| Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors F Janku, DS Hong, S Fu, SA Piha-Paul, A Naing, GS Falchook, ... Cell reports 6 (2), 377-387, 2014 | 283 | 2014 |
| Phase I/Ib clinical trial of sabatolimab, an anti–TIM-3 antibody, alone and in combination with spartalizumab, an anti–PD-1 antibody, in advanced solid tumors G Curigliano, H Gelderblom, N Mach, T Doi, D Tai, PM Forde, ... Clinical Cancer Research 27 (13), 3620-3629, 2021 | 270 | 2021 |
| A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas DS Hong, R Kurzrock, JG Supko, X He, A Naing, J Wheler, D Lawrence, ... Clinical cancer research 18 (12), 3396-3406, 2012 | 269 | 2012 |
| Cancer therapy directed by comprehensive genomic profiling: a single center study JJ Wheler, F Janku, A Naing, Y Li, B Stephen, R Zinner, V Subbiah, S Fu, ... Cancer research 76 (13), 3690-3701, 2016 | 267 | 2016 |
| PEGylated IL-10 (Pegilodecakin) induces systemic immune activation, CD8+ T cell invigoration and polyclonal T cell expansion in cancer patients A Naing, JR Infante, KP Papadopoulos, IH Chan, C Shen, NP Ratti, ... Cancer Cell 34 (5), 775-791. e3, 2018 | 262 | 2018 |
| Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline BD Santomasso, LJ Nastoupil, S Adkins, C Lacchetti, BJ Schneider, ... Journal of Clinical Oncology 39 (35), 3978-3992, 2021 | 260 | 2021 |
| Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors A Naing, KP Papadopoulos, KA Autio, PA Ott, MR Patel, DJ Wong, ... Journal of Clinical Oncology 34 (29), 3562-3569, 2016 | 259 | 2016 |
| FGFR a promising druggable target in cancer: Molecular biology and new drugs R Porta, R Borea, A Coelho, S Khan, A Araújo, P Reclusa, T Franchina, ... Critical reviews in oncology/hematology 113, 256-267, 2017 | 255 | 2017 |
| BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer GS Falchook, M Millward, D Hong, A Naing, S Piha-Paul, ... Thyroid 25 (1), 71-77, 2015 | 242 | 2015 |
Razelle Kurzrock, MDProfessor of Medicine, Medical College of WisconsinVerified email at mcw.edu